Jeff Yass’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32K | Buy |
36,328
+14,276
| +65% | +$15.2K | ﹤0.01% | 12943 |
|
|
2026
Q1 | $13.3K | Sell |
22,052
-16,514
| -43% | -$12.4K | ﹤0.01% | 12910 |
|
|
2025
Q4 | $29.7K | Sell |
38,566
-55,778
| -59% | -$50.3K | ﹤0.01% | 11878 |
|
|
2025
Q3 | $95.3K | Buy |
94,344
+80,937
| +604% | +$95.1K | ﹤0.01% | 11594 |
|
|
2025
Q2 | $17.8K | Sell |
13,407
-12,346
| -48% | -$16.8K | ﹤0.01% | 12352 |
|
|
2025
Q1 | $30.6K | Sell |
25,753
-221,224
| -90% | -$315K | ﹤0.01% | 12002 |
|
|
2024
Q4 | $403K | Buy |
246,977
+112,717
| +84% | +$298K | ﹤0.01% | 9198 |
|
|
2024
Q3 | $513K | Sell |
134,260
-1,195
| -0.9% | -$3.99K | ﹤0.01% | 8410 |
|
|
2024
Q2 | $397K | Sell |
135,455
-53,711
| -28% | -$172K | ﹤0.01% | 8813 |
|
|
2024
Q1 | $749K | Sell |
189,166
-72,052
| -28% | -$371K | ﹤0.01% | 7557 |
|
|
2023
Q4 | $1.3M | Buy |
261,218
+80,681
| +45% | +$401K | ﹤0.01% | 6349 |
|
|
2023
Q3 | $912K | Buy |
180,537
+24,585
| +16% | +$135K | ﹤0.01% | 6834 |
|
|
2023
Q2 | $784K | Sell |
155,952
-59,126
| -27% | -$387K | ﹤0.01% | 7244 |
|
|
2023
Q1 | $1.32M | Buy |
215,078
+96,915
| +82% | +$793K | ﹤0.01% | 6114 |
|
|
2022
Q4 | $1.56M | Buy |
118,163
+59,070
| +100% | +$417K | ﹤0.01% | 5193 |
|
|
2022
Q3 | $176K | Sell |
59,093
-92,007
| -61% | -$390K | ﹤0.01% | 11021 |
|
|
2022
Q2 | $552K | Buy |
151,100
+14,310
| +10% | +$68K | ﹤0.01% | 8026 |
|
|
2022
Q1 | $846K | Sell |
136,790
-160,510
| -54% | -$997K | ﹤0.01% | 7570 |
|
|
2021
Q4 | $2.41M | Sell |
297,300
-38,078
| -11% | -$410K | ﹤0.01% | 5076 |
|
|
2021
Q3 | $5M | Buy |
335,378
+208,047
| +163% | +$2.59M | ﹤0.01% | 3964 |
|
|
2021
Q2 | $1.6M | Buy |
+127,331
| New | +$994K | ﹤0.01% | 6471 |
|
|
2019
Q1 | – | Sell |
-4,761
| Closed | -$39.7K | – | 9577 |
|
|
2018
Q4 | $31K | Buy |
4,761
+3,983
| +512% | +$52.7K | ﹤0.01% | 8604 |
|
|
2018
Q3 | $13K | Buy |
+778
| New | +$14K | ﹤0.01% | 9032 |
|
|
2018
Q2 | – | Sell |
-1,895
| Closed | -$45K | – | 10177 |
|
|
2018
Q1 | $45K | Buy |
+1,895
| New | +$510K | ﹤0.01% | 8985 |
|
|
2017
Q1 | – | Sell |
-1,312
| Closed | -$328K | – | 9687 |
|
|
2016
Q4 | $328K | Buy |
+1,312
| New | +$298K | ﹤0.01% | 7808 |
|
|
2016
Q1 | – | Sell |
-923
| Closed | -$231K | – | 9487 |
|
|
2015
Q4 | $231K | Buy |
+923
| New | +$298K | ﹤0.01% | 8181 |
|
Other funds holding PDSB
QCM
MCM
Jeff Yass's PDSB Position: Q2 2026 in Review
Jeff Yass increased its PDS Biotechnology (PDSB) stake by 65% in Q2 2026, buying an estimated $15.2K and bringing the position to 36,328 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #12943.
Jeff Yass first reported a position in PDSB in Q4 2015 and has held it in 26 quarters since. The position peaked at $5M in Q3 2021. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.
- Jeff Yass held 36,328 shares of PDS Biotechnology worth $32K as of Q2 2026.
- Jeff Yass bought 14,276 PDS Biotechnology shares in Q2 2026, an estimated $15.2K.
- PDS Biotechnology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12943 holding.
- Jeff Yass first reported a position in PDS Biotechnology in Q4 2015 and has held it in 26 quarters since.
- Jeff Yass's PDS Biotechnology position peaked at $5M in Q3 2021.
- 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.